Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced today that its NETHERTON NOW awareness campaign has generated nearly 2 million video views and more than 24 million impressions globally since its launch in February 2025. The milestone comes as the company recognizes Rare Disease Day® 2026, which falls on the last day of February and aims to raise awareness for rare conditions affecting hundreds of millions worldwide.
Netherton Syndrome is a rare genetic skin disorder caused by mutations in the SPINK5 gene, leading to excessive skin shedding, chronic inflammation, recurrent infections, dehydration, and a severely compromised skin barrier. The disease can be life-threatening, particularly in infancy, with an estimated 10–20% of newborns not surviving. Those who survive often face lifelong complications, severe pain, and significant quality-of-life burdens.
Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, emphasized the campaign's impact: "When we launched NETHERTON NOW at the beginning of Rare Disease Month last year, we hoped it would resonate, but the response has far surpassed anything we anticipated. Individuals who had previously lived in silence with their suffering now have a platform to share their stories, connect with one another, and help bring greater understanding of Netherton Syndrome to the broader medical and advocacy communities."
In conjunction with Rare Disease Day, the campaign released its latest video, "If There Was a Cure," featuring patients and families reflecting on what meaningful treatment progress would mean in their lives. The video can be viewed at https://youtu.be/AIcGZQEumF0?si=5d226QrYKR3m-hHC.
Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals, stressed the importance of translating awareness into action: "Our responsibility extends beyond just creating visibility. It includes advancing rigorous clinical research, pursuing regulatory pathways with discipline, and working to ensure broad access to potential treatments. Patients and families deserve not only to be seen and heard, but to have safe, effective, and accessible treatments."
Quoin's lead investigational candidate, QRX003, is currently in late-stage pivotal clinical trials for Netherton Syndrome. The company remains committed to addressing the significant unmet medical needs associated with this devastating disease. For more information about Rare Disease Day, visit www.rarediseaseday.org. To learn more about Netherton Syndrome and the NETHERTON NOW campaign, visit https://nethertonnow.com.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. Its pipeline includes four products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, and angiofibromas. Forward-looking statements in this release are subject to risks and uncertainties, including those detailed in the company's SEC filings.
